<?xml version="1.0" encoding="UTF-8"?>
<p>Although CQ and HCQ are relatively well-tolerated, both drugs are associated with systemic adverse effects, including QT syndrome, hypoglycemia, hepatitis, pancreatitis, neutropenia, retinopathy, anaphylaxis, and cardiac toxicities.
 <sup>
  <xref rid="bibr7-2049936120947517" ref-type="bibr">7</xref>
 </sup> The United States Food and Drug Administration (FDA) has issued warnings on CQ/HCQ, particularly based on the associated cardiac side-effects.
 <sup>
  <xref rid="bibr8-2049936120947517" ref-type="bibr">8</xref>
 </sup> The CQ/HCQ, either alone or in combination with other drugs like azithromycin, can cause possible cardiac complications, including conduction defects, such as bundle branch blocks, atrioventricular blocks, QT prolongation, torsades de point (TdP), and even dangerous ventricular arrhythmias. Although the CQ and HCQ use during pregnancy and in lactating mothers are believed to be safe,
 <sup>
  <xref rid="bibr9-2049936120947517" ref-type="bibr">9</xref>
  <xref rid="bibr10-2049936120947517" ref-type="bibr"/>â€“
  <xref rid="bibr11-2049936120947517" ref-type="bibr">11</xref>
 </sup> they should be avoided in children due to narrow therapeutic and toxic windows. Children can suffer from apnea, seizures, and arrhythmias if they exceed the recommended therapeutic dose.
 <sup>
  <xref rid="bibr12-2049936120947517" ref-type="bibr">12</xref>
 </sup>
</p>
